Related Experiment Video
Updated: Mar 2, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Risk and Benefit in Personalised Medicine: An End User View
1a Genetic Alliance , UK.
Abstract:
Personalised, or stratified, medicine is creating opportunities for the development of targeted therapies for many hitherto unmet clinical needs. For patients and families this is a cause for optimism. But it is unlikely that these novel therapies will provide complete cures. Rather they will address some but not all symptoms of a condition. In such circumstances, early engagement with patients and families will ensure that developments are targeted at those aspects of a condition which really matter, not just those that are easy to count. This will make the development process more efficient, and improve the likelihood that patients will be able to access therapies if the development process is successful.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenomics: Identification of New Drug Targets
Dosage Regimen: Individualization
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

